The panel discussion feature industry leaders discussing such questions as:

• Do you see the role of in vitro tox assays increasing in importance and frequency prior to animal tox testing?  What in vitro assays are most often used now (other than ADME) prior to animal tox? 
• Would you only implement a technology that you would run in-house?  
• How does potential regulatory acceptance factor into a decision to adopt a new technology (--or-- does good science triumph over regulatory uncertainty)? 
• To what extent are stem cells being used for in vitro cell-based assays to identify drugs with higher efficacy and minimal toxicity? What are the barriers that must be overcome for this approach to accelerate progress? 
• To what extent do you need to quality/validate a novel technology so that your project team will accept it?   
• At what level of management is the decision taken to evaluate and adopt a new technology? 
  

Please tell us what type of company you represent:		Drug developer (small or large molecules)CRO or other service providerTool/platform vendorAcademiaGovernmentOther
First Name:
Last Name:
Title:
Department:
Company:
Phone Number:
E-Mail Address:
Would you like to learn more about DSEC's Collaborative Technology Evaluation (CTE) as either a participant or sponsor?:		Yes, please contact me regarding participation.Yes, please contact me regarding sponsorshipNo, thank you.